Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status-Reference-Cited by-同舟云学术

Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status

Published:2024-08-24 Issue:1 Volume:24 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Taniguchi Yoshihiko,Tamiya Akihiro,Osuga Mitsuo,Harada Daijiro,Isa Shun-ichi,Nakamura Keiichi,Mizumori Yasuyuki,Shinohara Tsutomu,Yanai Hidetoshi,Nakatomi Katsumi,Oki Masahide,Mori Masahide,Kuwako Tomohito,Yamazaki Koji,Tamura Atsuhisa,Ando Masahiko,Koh Yasuhiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12890-024-03212-5.pdf

Reference29 articles.

1. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93. https://doi.org/10.18632/oncotarget.12587.

2. Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;3:CD010383. https://doi.org/10.1002/14651858.CD010383.pub2.

3. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2016;376:629–40. https://doi.org/10.1016/j.lungcan.2018.10.027.

4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2017;378:113–25. https://doi.org/10.1056/NEJMoa1713137.

5. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. https://doi.org/10.1056/NEJMoa1913662.